ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GENSCI142

A development code. Also written as “GenSci142 capsule” and “GenSci142”.

Its studies are mostly in Vaginosis, Bacterial, led by Changchun GeneScience Pharmaceutical.

Furthest: phase 1, since Nov 27, 20252 company-led studies, 2 open or runningNext primary completion: Jan 5, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical22 open or runningphase 1since Nov 27, 2025Nov 27, 2025Jan 5, 2027phase 1 · NCT07663838

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2025First study: phase 1 study in Vaginosis, BacterialFirst studyNCT07302035 · 30 planned · China
  2. Jun 5, 2026Phase 1 study in Vaginosis, BacterialNCT07663838 · 42 planned · China

Ahead

  1. Jan 5, 2027Primary completion: phase 1 study in Vaginosis, BacterialNCT07663838

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07663838Vaginosis, Bacterial · China1RecruitingJan 5, 202742
NCT07302035Vaginosis, Bacterial · China1Not yet recruitingSep 202630

How it is read

Names in the registry

  • “GenSci142 capsule”, 1 entry
  • “GenSci142”, 1 entry

Codes read as this program: GENSCI142.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.